🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Unity Biotech stock PT cut by H.C. Wainwright on ASPIRE trial update

EditorIsmeta Mujdragic
Published 04/16/2024, 06:53 AM
UBX
-

On Tuesday, H.C. Wainwright adjusted its outlook on Unity Biotechnology Inc (NASDAQ:UBX), lowering the price target to $8 from the previous $10 while maintaining a Buy rating on the stock. The firm's decision comes in anticipation of the Phase 2B ASPIRE trial data for the treatment of diabetic macular edema (DME), expected in the fourth quarter of 2024.

Unity Biotechnology is in the spotlight for its development of a novel senolytic small molecule, Bcl-xL inhibitor foselutoclax (UBX1325), which is believed to offer potential disease-modifying benefits for patients with DME. The company's approach focuses on the elimination of detrimental senescent cells and inflammatory SASP signaling in the retina, a method that could revolutionize the treatment of DME.

Recent publications, including preclinical and Phase 1 results, have highlighted the significant role of retinal senescent cells in DME pathology. Unity Biotechnology's UBX1325 is designed to therapeutically eliminate these cells, potentially reducing diabetes-induced retinal vascular leakage and preserving retinal function. This therapeutic strategy is supported by findings published in Nature Medicine in 2024.

The revised price target reflects adjustments in the projected launch revenue timeline for foselutoclax, now expected in 2026 rather than 2025. Additionally, H.C. Wainwright has temporarily removed modeled revenue from potential clinical developments in diabetic retinopathy (DR) and age-related macular degeneration (AMD (NASDAQ:AMD)) from its valuation. However, the firm identifies the lead optimization development of UBB2048 in retinal vascular diseases as a potential upside.

Despite the reduction in the price target, H.C. Wainwright reiterates its confidence in Unity Biotechnology's stock with a Buy rating. The firm emphasizes the significance of the upcoming Phase 2B ASPIRE trial data, which could align with the successful findings from earlier phases of the trial.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.